Abstract
INTRODUCTION SARS-CoV-2 testing is one of the options to combat COVID-19 in Kenya. In the first COVID-19 year there was limited tapping of the private sector’s potential to scale up testing in Kenya. In April 2020, we initiated a unique public-private partnership (PPP) project in Kisumu County connecting the private sector to centralized testing supported by the ministry of health (MoH), ‘COVID-Dx’, to accelerate the local response to COVID-19. We aimed to demonstrate this PPP’s performance as a replicable model for effective public-private collaboration in responding to the COVID-19 pandemic in similar settings.
METHODS KEMRI, Department of Health Kisumu County, PharmAccess Foundation, and local faith-based and private healthcare facilities collaborated in COVID-Dx. COVID-Dx was implemented from June 01, 2020, to March 31, 2021, in Kisumu County, Kenya. Trained laboratory technologists in participating healthcare facilities collected nasopharyngeal and oropharyngeal samples from patients meeting the MoH COVID-19 case definition. Samples were tested at the central laboratory in KEMRI via SARS-CoV-2 RT-PCR. Healthcare workers in participating facilities collected data using the digitized MoH COVID-19 Case Identification Form. We shared aggregated results from these data via (semi-) live dashboard to all relevant stakeholders. We did descriptive statistical analyses using Stata 16 to inform project processes.
RESULTS Nine facilities participated in the project. A total of 4,324 PCR tests for SARS-CoV-2 were done, with 425 positives. We noted differences in positivity rates between the facilities. Healthcare workers were the largest group tested in the project, 1009, representing 43% of the Kisumu healthcare workforce.
CONCLUSION COVID-Dx can serve as a PPP model for scale-up testing and epidemic preparedness, especially in LMICs. Digitizing the MoH case report form improved reporting efficiency, demonstrating that digital is the way forward. The COVID-Dx PPP has led to another collaboration with Kisumu County aimed towards extending the COVID-Dx model to other counties.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was financially supported by the Achmea Foundation, Pfizer Foundation, and the Netherlands Ministry of Foreign Affairs. The funders did not have any role in study design, data collection, analysis, interpretation, summarizing the data or decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical clearance for this project was obtained from Jaramogi Oginga Odinga Teaching & Referral Hospital (JOOTRH) on June 16, 2020, with approval number IERC/JOOTRH/230/2020. KEMRI also provided ethical clearance on September 30, 2020, with approval number KEMRI KEMRI/SERU/CGHR/05-05/4038. Research License was obtained from the National Commission for Science, Technology, and Innovation (NACOSTI) on July 6, 2020 (NACOSTI/P/20/5616). The roll-out of this project was in complete coordination with the Kisumu Department of Health. Sample collection in patients in this project was voluntary.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to the privacy of patient data, datasets associated with this project are not publicly available. Anonymized and aggregated data are available from the authors upon request.
Abbreviations
- CCIF
- COVID Case Identification Form
- COVAX
- COVID-19 Global Vaccine Access
- COVID-19
- coronavirus disease of 2019
- DoH
- Department of Health
- GDPR
- General Data Protection Regulation
- GFATM
- The Global Fund to Fight AIDS, Tuberculosis and Malaria
- HIPAA
- Health Insurance Portability and Accountability Act of 1996
- KEMRI
- Kenya Medical Research Institute
- MoH
- Ministry of Health
- NGO
- non-governmental organization
- PCR
- polymerase chain reaction
- PEPFAR
- President’s Emergency Plan for AIDS Relief
- PPE
- personal protective equipment
- PPP
- public-private partnership
- RDT
- rapid diagnostic test
- ToT
- trainers of trainers
- UHC
- universal health coverage
- VTM
- viral transport medium
